Literature DB >> 26593849

Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Donna M Wilcock1, Frederick A Schmitt2, Elizabeth Head3.   

Abstract

Down syndrome (DS) is a common cause of intellectual disability and is also associated with early age of onset of Alzheimer's disease (AD). Due to an extra copy of chromosome 21, most adults over 40years old with DS have beta-amyloid plaques as a result of overexpression of the amyloid precursor protein. Cerebrovascular pathology may also be a significant contributor to neuropathology observed in the brains of adults with DS. This review describes the features of cardiovascular dysfunction and cerebrovascular pathology in DS that may be modifiable risk factors and thus targets for interventions. We will describe cerebrovascular pathology, the role of co-morbidities, imaging studies indicating vascular pathology and the possible consequences. It is clear that our understanding of aging and AD in people with DS will benefit from further studies to determine the role that cerebrovascular dysfunction contributes to cognitive health. This article is part of a Special Issue entitled: Vascular Contributions to Cognitive Impairment and Dementia edited by M. Paul Murphy, Roderick A. Corriveau and Donna M. Wilcock.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Beta-amyloid; Cerebral amyloid angiopathy; Hypertension; Hypotension; Microhemorrhages; Moyamoya; Sleep apnea; Stroke

Mesh:

Substances:

Year:  2015        PMID: 26593849      PMCID: PMC4821721          DOI: 10.1016/j.bbadis.2015.11.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  110 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

2.  Precocious aging and dementia in patients with Down's syndrome.

Authors:  K Wisniewski; J Howe; D G Williams; H M Wisniewski
Journal:  Biol Psychiatry       Date:  1978-10       Impact factor: 13.382

Review 3.  Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia.

Authors:  Rufus O Akinyemi; Elizabeta B Mukaetova-Ladinska; Johannes Attems; Masafumi Ihara; Raj N Kalaria
Journal:  Curr Alzheimer Res       Date:  2013-07       Impact factor: 3.498

4.  Moyamoya and Down syndrome. Clinical and radiological features.

Authors:  S C Cramer; R L Robertson; E C Dooling; R M Scott
Journal:  Stroke       Date:  1996-11       Impact factor: 7.914

5.  Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease.

Authors:  Daraspreet S Kainth; Saqib A Chaudhry; Hunar S Kainth; Fareed K Suri; Adnan I Qureshi
Journal:  Neurosurgery       Date:  2013-02       Impact factor: 4.654

6.  The four ages of Down syndrome.

Authors:  Alan H Bittles; Carol Bower; Rafat Hussain; Emma J Glasson
Journal:  Eur J Public Health       Date:  2006-07-19       Impact factor: 3.367

7.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Authors:  S E Stoltzner; T J Grenfell; C Mori; K E Wisniewski; T M Wisniewski; D J Selkoe; C A Lemere
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

8.  Does Down's syndrome support the homocysteine theory of atherogenesis? Experience in elderly subjects with trisomy 21.

Authors:  Federico Licastro; Alessandro Marocchi; Silvana Penco; Elisa Porcellini; Domenico Lio; Giada Dogliotti; Massimiliano M Corsi
Journal:  Arch Gerontol Geriatr       Date:  2006-03-14       Impact factor: 3.250

9.  Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies.

Authors:  Tiffany L Sudduth; Abigail Greenstein; Donna M Wilcock
Journal:  J Neurosci       Date:  2013-06-05       Impact factor: 6.167

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  20 in total

Review 1.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

2.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

4.  Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease.

Authors:  María Carmona-Iragui; Mircea Balasa; Bessy Benejam; Daniel Alcolea; Susana Fernández; Laura Videla; Isabel Sala; María Belén Sánchez-Saudinós; Estrella Morenas-Rodriguez; Roser Ribosa-Nogué; Ignacio Illán-Gala; Sofía Gonzalez-Ortiz; Jordi Clarimón; Frederick Schmitt; David K Powell; Beatriz Bosch; Albert Lladó; Michael S Rafii; Elizabeth Head; José Luis Molinuevo; Rafael Blesa; Sebastián Videla; Alberto Lleó; Raquel Sánchez-Valle; Juan Fortea
Journal:  Alzheimers Dement       Date:  2017-04-29       Impact factor: 21.566

Review 5.  Down syndrome, beta-amyloid and neuroimaging.

Authors:  Elizabeth Head; Alex M Helman; David Powell; Frederick A Schmitt
Journal:  Free Radic Biol Med       Date:  2017-09-19       Impact factor: 7.376

6.  Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan.

Authors:  Harry LeVine; H Peter Spielmann; Sergey Matveev; Francesca Macchiavello Cauvi; M Paul Murphy; Tina L Beckett; Katie McCarty; Ira T Lott; Eric Doran; Frederick Schmitt; Elizabeth Head
Journal:  Neurobiol Aging       Date:  2017-03-14       Impact factor: 4.673

Review 7.  Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors:  Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal:  Mol Neurodegener       Date:  2020-07-16       Impact factor: 14.195

Review 8.  Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.

Authors:  Steven M Greenberg; Brian J Bacskai; Mar Hernandez-Guillamon; Jeremy Pruzin; Reisa Sperling; Susanne J van Veluw
Journal:  Nat Rev Neurol       Date:  2019-12-11       Impact factor: 42.937

9.  Calcineurin proteolysis in astrocytes: Implications for impaired synaptic function.

Authors:  Melanie M Pleiss; Pradoldej Sompol; Susan D Kraner; Hafiz Mohmmad Abdul; Jennifer L Furman; Rodney P Guttmann; Donna M Wilcock; Peter T Nelson; Christopher M Norris
Journal:  Biochim Biophys Acta       Date:  2016-05-20

Review 10.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.